A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Phase 1 Study of AK002, a Novel Siglec-8 Selective Monoclonal Antibody, in Healthy Subjects

Authors:
  • HRHenrik S. Rasmussen
    Henrik S. Rasmussen
  • ACAlan T. Chang
    Alan T. Chang
  • NTNenad Tomasevic
    Nenad Tomasevic
  • CBChristopher Bebbington
    Christopher Bebbington
Publisher website
Google Scholar
Abstract
No abstract available